Objective To observe the clinical efficacy of modified Zexie Decoction in treatment of elderly patients with grade 1 of essential hypertension(extremely high risk)differentiated as syndrome of excessive phlegm and dampness.Methods From May 2021 to April 2023,103 elderly patients with grade 1 of essential hypertension(extremely high risk)in the Department of Geriatric Diseases in the authors'hospital were selected as research objects,and they were randomly divided into control group(n=51)and study group(n=52).The control group received lifestyle interventions,while the study group was treated with modified Zexie Decoction on the basis of the control group.After two weeks of treatment,the clinical efficacy,the score of traditional Chinese medicine symptoms,blood pressure,blood lipid level,and maximum intima-media thickness of the carotid artery(dIMTmax)were compared between the two groups.Results The total effective rate in the study group was 90.38％,which was significantly higher than 56.86％in the control group(P＜0.05).After treatment,the scores of primary and secondary symptoms in both groups decreased significantly when compared to those before treatment,and the scores of primary and secondary symptoms in the study group were significantly lower than those in the control group(P＜0.0 5).After treatment,the systolic and diastolic blood pressures in both groups decreased significantly when compared to those before treatment,and the systolic and diastolic blood pressures in the study group were significantly lower than those in the control group(P＜0.05).After treatment,the levels of total cholesterol,triglycerides and low-den-sity lipoprotein cholesterol decreased significantly in both groups,while high-density lipoprotein cho-lesterol level increased significantly,and the levels of total cholesterol,triglycerides and low-density lipoprotein cholesterol in the study group were significantly lower than those in the control group,but the high-density lipoprotein cholesterol level was significantly higher than that in the control group(P＜0.05).After treatment,the dIMTmax in the treatment group was(0.92±0.12)mm,which was significantly less than(1.10±0.15)mm in the control group(P＜0.05).Conclusion Modified Zexie Decoction can effectively improve clinical symptoms in elderly patients with essential hyperten-sion,regulate blood pressure and lipid levels,alleviate vascular endothelial injury,and reduce the carotid intima-media thickness.

Objective To observe the clinical efficacy of modified Zexie Decoction in treatment of elderly patients with grade 1 of essential hypertension(extremely high risk)differentiated as syndrome of excessive phlegm and dampness.Methods From May 2021 to April 2023,103 elderly patients with grade 1 of essential hypertension(extremely high risk)in the Department of Geriatric Diseases in the authors'hospital were selected as research objects,and they were randomly divided into control group(n=51)and study group(n=52).The control group received lifestyle interventions,while the study group was treated with modified Zexie Decoction on the basis of the control group.After two weeks of treatment,the clinical efficacy,the score of traditional Chinese medicine symptoms,blood pressure,blood lipid level,and maximum intima-media thickness of the carotid artery(dIMTmax)were compared between the two groups.Results The total effective rate in the study group was 90.38％,which was significantly higher than 56.86％in the control group(P＜0.05).After treatment,the scores of primary and secondary symptoms in both groups decreased significantly when compared to those before treatment,and the scores of primary and secondary symptoms in the study group were significantly lower than those in the control group(P＜0.0 5).After treatment,the systolic and diastolic blood pressures in both groups decreased significantly when compared to those before treatment,and the systolic and diastolic blood pressures in the study group were significantly lower than those in the control group(P＜0.05).After treatment,the levels of total cholesterol,triglycerides and low-den-sity lipoprotein cholesterol decreased significantly in both groups,while high-density lipoprotein cho-lesterol level increased significantly,and the levels of total cholesterol,triglycerides and low-density lipoprotein cholesterol in the study group were significantly lower than those in the control group,but the high-density lipoprotein cholesterol level was significantly higher than that in the control group(P＜0.05).After treatment,the dIMTmax in the treatment group was(0.92±0.12)mm,which was significantly less than(1.10±0.15)mm in the control group(P＜0.05).Conclusion Modified Zexie Decoction can effectively improve clinical symptoms in elderly patients with essential hyperten-sion,regulate blood pressure and lipid levels,alleviate vascular endothelial injury,and reduce the carotid intima-media thickness.

AIM: To observe the effects of Tangshen formula (TSF) treatment on lipid efflux and uptake in sodium palmitate (PA) induced RAW264.7 macrophages. METHODS: After 200 μmol/L PA induced RAW264.7 macrophages, TSF and PGC-1α-siRNA were given to intervene respectively. The lipid content in the cells was detected by ELISA kit; intracellular lipid droplet deposition was detected by BODIPY 493/503 and Filipin staining. Western blot and Real-time PCR were used to detect the expression of PGC-1α, LXR, ABCA1 and CD36. RESULTS: TSF diminished the levels of TC, TG and intracellular lipid droplet deposition in PA-induced RAW264.7 macrophages. Western blot and Real-time PCR analysis showed that TSF could up-regulate the expression of PGC-1α, LXR, ABCA1 and down-regulate the expression of CD36. Furthermore, silencing PCG-1α by SiRNA significantly suppressed the effects of upregulating the expression of PGC-1α, LXR and ABCA1, and downregulating the CD36 expression with TSF treatment. CONCLUSION: TSF may extenuate intracellular lipid droplet deposition in macrophages by upregulating cholesterol efflux through activating the PGC-1α/LXR/ABCA1 pathway and inhibiting lipid uptake through down-regulateing the expression of CD36.

AIM: To observe the effect of Tangshen formula (TSF) treatment on TGF-β1/Smad3 pathway and cellular cholesterol efflux and explore its potential mechanism in HG-induced mouse tubular epithelial cells (mTECs). METHODS: After 25 mmol/L high glucose induced mTECs, TSF and Smad3 inhibitor SIS3 were given to intervene respectively. The lipid content in the cells was detected by ELISA kit; TGF-β1/Smad3 pathway and PGC-1α, LXR, ABCA1, ABCG1 were detected by Western blot and real-time PCR. RESULTS: TSF diminished the levels of TC, TG, LDL-C and increased the levels of HDL-C in HG-induced mTECs. Western blot and real-time PCR analysis showed that expression levels of TGF-β1, Smad3, Collagen and Fibronectin were significantly downregulated in the HG-induced mTECs with TSF and SIS3 treatment. And PGC-1α, LXR, ABCA1, ABCG1 expression levels were significantly upregulated in the HG-induced mTECs with TSF and SIS3 treatment. CONCLUSION: TSF can promote the cellular cholesterol efflux in HG-induced mTECs vis suppression of TGF-β1/Smad3 pathway.